BridgeBio have demonstrably improved this course of a novel therapy for ATTR-CM, employing Attruby. Early patient data suggests potential outcomes for individuals suffering by the severe condition. This emphasis highlights BridgeBio's focus to managing critical patient needs in this heart disease